You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK):普吉華®一線治療RET融合陽性晚期非小細胞肺癌註冊研究達預期,擬遞交新適應證上市申請
格隆匯 06-24 08:06

格隆匯6月24日丨基石藥業-B(02616.HK)發佈公吿,選擇性RET抑制劑普吉®在全球I/II期ARROW關鍵性試驗的中國患者註冊研究結果。研究數據顯示,普吉®(普拉替尼膠囊)在一線治療轉染重排(“RET”)融合陽性晚期非小細胞肺癌(“NSCLC”)中國患者中具有優越和持久的臨牀抗腫瘤活性,這與全球數量一致。整體安全可控,且沒有發現新的安全信號。普拉替尼是一種強效、選擇性RET抑制劑,由基石藥業合作伙伴Blueprint Medicines Corporation(NASDAQ:BPMC)(“Blueprint Medicines”)開發。

ARROW研究中國主要研究者、廣東省人民醫院吳一龍教授表示:“目前,國內臨牀上針對RET融合陽性NSCLC患者的一線標準治療方案為含鉑雙藥化療,但仍然亟需新的治療方式。普吉華®在國內獲批使得RET融合陽性NSCLC治療步入了RET抑制劑時代。此次普吉華®一線治療RET融合陽性NSCLC中國患者的註冊研究取得成功,令我們非常期待該藥物的更多、更廣適應證能夠在中國獲批上市。”

基石藥業首席醫學官楊建新博士表示:“我們激動的看到普吉華®在中國RET融合陽性一線NSCLC患者中取得了優異的療效結果,並且安全可控,這一結果進一步夯實了普吉華®的循證醫學證據。我們感謝所有參與臨牀研究的研究者,患者和家屬。我們很快會啟動與NMPA的溝通,期待可以早日造福更多患者。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account